{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T11:01:17Z","timestamp":1766401277705,"version":"3.41.0"},"posted":{"date-parts":[[2025,5,9]]},"group-title":"In Review","reference-count":64,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,5,2]]},"abstract":"<title>Abstract<\/title>\n        <p>Treatment of JAK2V617F driven myeloproliferative neoplasms (MPNs) with Ruxolitinib (JAK inhibitor, JAKi) has shown limited disease-modifying benefits and has led to the search for other pathways as potential therapeutic targets for this disease. We investigated the effects of Smoothened inhibition (SMOi) using the small-molecule inhibitor PF-04449913 (PF-13) in a JAK2V617F transgenic mouse model that recapitulates many of the phenotypes of MPNs including bone marrow fibrosis and splenomegaly. We show both that hedgehog (Hh) signaling pathway is activated in JAK2V617F cells and that SMOi reduces splenomegaly in JAK2V617F mice. In a murine bone marrow transplant model, we show that SMOi also reduces JAK2V617F allelic burden. JAK2V617F mice show increased pERK and NF-\u03baB signaling, which is reduced with SMOi. Finally, we found that SMO inhibitor blocks bone marrow fibrosis by reducing TGF-\u03b2 signaling. In conclusion, this report provides critical insight into the mechanism of action of SMO inhibitors in JAK2V617F associated MPN.<\/p>","DOI":"10.21203\/rs.3.rs-6580439\/v1","type":"posted-content","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T16:52:03Z","timestamp":1746809523000},"source":"Crossref","is-referenced-by-count":0,"title":["Smoothened Inhibitor, PF-04449913 Inhibits the Development of Myelofibrosis in a JAK2V617F Transgenic Mouse Model by Reducing TGF-\u03b2 and MAPK Signaling Pathways"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7472-822X","authenticated-orcid":false,"given":"Akil","family":"Merchant","sequence":"first","affiliation":[{"name":"Cedars-Sinai Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parvesh","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"University of Southern California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohan","family":"Singh","sequence":"additional","affiliation":[{"name":"University of Southern California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tucker","family":"Lemos","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Fargal","sequence":"additional","affiliation":[{"name":"Tanta University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imran","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"University of Southern California\u2013Keck School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey","family":"O'Connell","sequence":"additional","affiliation":[{"name":"University of Southern California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4323-4301","authenticated-orcid":false,"given":"Zhizhuang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Uni of Oklahoma Health Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1242\/JCS.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings JS","year":"2004","unstructured":"Rawlings JS, Rosler KM, Harrison DA. The JAK\/STAT signaling pathway. J Cell Sci 2004;117:1281\u20133. https:\/\/doi.org\/10.1242\/JCS.00963.","journal-title":"J Cell Sci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/ONC.2012.347","article-title":"JAK\/STAT signaling in hematological malignancies","volume":"32","author":"Vainchenker W","year":"2013","unstructured":"Vainchenker W, Constantinescu SN. JAK\/STAT signaling in hematological malignancies. Oncogene 2013;32:2601\u201313. https:\/\/doi.org\/10.1038\/ONC.2012.347.","journal-title":"Oncogene"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter EJ","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(05)71142-9.","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMOA051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics R","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779\u201390. https:\/\/doi.org\/10.1056\/NEJMOA051113.","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"7037","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James C","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005 434:7037 2005;434:1144\u20138. https:\/\/doi.org\/10.1038\/nature03546.","journal-title":"Nature 2005"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/J.CCR.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine RL","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387\u201397. https:\/\/doi.org\/10.1016\/J.CCR.2005.03.023.","journal-title":"Cancer Cell"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/BLOOD-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker W","year":"2017","unstructured":"Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 2017;129:667\u201379. https:\/\/doi.org\/10.1182\/BLOOD-2016-10-695940.","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3322\/CAAC.20009","article-title":"Advances in understanding and management of myeloproliferative neoplasms","volume":"59","author":"Vannucchi AM","year":"2009","unstructured":"Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 2009;59:171\u201391. https:\/\/doi.org\/10.3322\/CAAC.20009.","journal-title":"CA Cancer J Clin"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/ASHEDUCATION-2006.1.233","article-title":"Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders","author":"Levine RL","year":"2006","unstructured":"Levine RL, Wernig G. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program 2006. https:\/\/doi.org\/10.1182\/ASHEDUCATION-2006.1.233.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/J.LEUKRES.2006.08.018","article-title":"Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence","volume":"31","author":"Benson DM","year":"2007","unstructured":"Benson DM, Elder PJ, Lin TS, Blum W, Penza S, Avalos B, et al. Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence. Leuk Res 2007;31:1069\u201375. https:\/\/doi.org\/10.1016\/J.LEUKRES.2006.08.018.","journal-title":"Leuk Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/BLOOD-2011-08-372904","article-title":"The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation","volume":"119","author":"Scott BL","year":"2012","unstructured":"Scott BL, Gooley TA, Sorror ML, Rezvani AR, Linenberger ML, Grim J, et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 2012;119:2657. https:\/\/doi.org\/10.1182\/BLOOD-2011-08-372904.","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1517\/13543784.2012.721352","article-title":"JAK2 inhibitors in the treatment of myeloproliferative neoplasms","volume":"21","author":"Tibes R","year":"2012","unstructured":"Tibes R, Bogenberger JM, Geyer HL, Mesa RA. JAK2 inhibitors in the treatment of myeloproliferative neoplasms. Expert Opin Investig Drugs 2012;21:1755\u201374. https:\/\/doi.org\/10.1517\/13543784.2012.721352.","journal-title":"Expert Opin Investig Drugs"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMOA1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison C","year":"2012","unstructured":"Harrison C, Kiladjian J-J, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787\u201398. https:\/\/doi.org\/10.1056\/NEJMOA1110556.","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMOA1110557\/SUPPL_FILE\/NEJMOA1110557_DISCLOSURES.PDF","article-title":"A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis","volume":"366","author":"Verstovsek S","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. New England Journal of Medicine 2012;366:799\u2013807. https:\/\/doi.org\/10.1056\/NEJMOA1110557\/SUPPL_FILE\/NEJMOA1110557_DISCLOSURES.PDF.","journal-title":"New England Journal of Medicine"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/BLOOD-2011-11-395228","article-title":"JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths","volume":"119","author":"Tefferi A","year":"2012","unstructured":"Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 2012;119:2721\u201330. https:\/\/doi.org\/10.1182\/BLOOD-2011-11-395228.","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMOA1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek S","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117\u201327. https:\/\/doi.org\/10.1056\/NEJMOA1002028.","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/S11899-020-00596-Z","article-title":"The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib","volume":"15","author":"Patel AA","year":"2020","unstructured":"Patel AA, Odenike O. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib. Curr Hematol Malig Rep 2020;15:409\u201318. https:\/\/doi.org\/10.1007\/S11899-020-00596-Z.","journal-title":"Curr Hematol Malig Rep"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1182\/BLOOD-2003-09-3347","article-title":"Indian hedgehog gene transfer augments hematopoietic support of human stromal cells including NOD\/SCID-beta2m-\/- repopulating cells","volume":"104","author":"Kobune M","year":"2004","unstructured":"Kobune M, Ito Y, Kawano Y, Sasaki K, Uchida H, Nakamura K, et al. Indian hedgehog gene transfer augments hematopoietic support of human stromal cells including NOD\/SCID-beta2m-\/- repopulating cells. Blood 2004;104:1002\u20139. https:\/\/doi.org\/10.1182\/BLOOD-2003-09-3347.","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1371\/JOURNAL.PONE.0041604","article-title":"Gene regulatory networks controlling hematopoietic progenitor niche cell production and differentiation in the Drosophila lymph gland","author":"Tokusumi Y","year":"2012","unstructured":"Tokusumi Y, Tokusumi T, Shoue DA, Schulz RA. Gene regulatory networks controlling hematopoietic progenitor niche cell production and differentiation in the Drosophila lymph gland. PLoS One 2012;7. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0041604.","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/J.EXPHEM.2013.05.287","article-title":"Nonhematopoietic cells represent a more rational target of in vivo hedgehog signaling affecting normal or acute myeloid leukemia progenitors","volume":"41","author":"Boyd AL","year":"2013","unstructured":"Boyd AL, Salci KR, Shapovalova Z, McIntyre BAS, Bhatia M. Nonhematopoietic cells represent a more rational target of in vivo hedgehog signaling affecting normal or acute myeloid leukemia progenitors. Exp Hematol 2013;41:858\u2013869.e4. https:\/\/doi.org\/10.1016\/J.EXPHEM.2013.05.287.","journal-title":"Exp Hematol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-241703","article-title":"Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors","author":"Merchant A","unstructured":"Merchant A, Joseph G, Wang Q, Brennan S, Matsui W. Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors. Blood 2010;115. https:\/\/doi.org\/10.1182\/blood-2009-09-241703."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-18","article-title":"Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies","volume":"7","author":"Tibes R","year":"2014","unstructured":"Tibes R, Mesa RA. Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies. J Hematol Oncol 2014;7. https:\/\/doi.org\/10.1186\/1756-8722-7-18.","journal-title":"J Hematol Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/J.CHEMBIOL.2017.02.010","article-title":"Hedgehog Signaling: From Basic Biology to Cancer Therapy","volume":"24","author":"Wu F","year":"2017","unstructured":"Wu F, Zhang Y, Sun B, McMahon AP, Wang Y. Hedgehog Signaling: From Basic Biology to Cancer Therapy. Cell Chem Biol 2017;24:252\u201380. https:\/\/doi.org\/10.1016\/J.CHEMBIOL.2017.02.010.","journal-title":"Cell Chem Biol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0070-2153(03)53002-2","article-title":"Developmental roles and clinical significance of hedgehog signaling","volume":"53","author":"McMahon AP","year":"2003","unstructured":"McMahon AP, Ingham PW, Tabin CJ. Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol 2003;53:1\u2013114. https:\/\/doi.org\/10.1016\/S0070-2153(03)53002-2.","journal-title":"Curr Top Dev Biol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/FONC.2022.960943","article-title":"The hedgehog pathway in hematopoiesis and hematological malignancy","author":"Lemos T","year":"2022","unstructured":"Lemos T, Merchant A. The hedgehog pathway in hematopoiesis and hematological malignancy. Front Oncol 2022;12. https:\/\/doi.org\/10.3389\/FONC.2022.960943.","journal-title":"Front Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1182\/BLOOD.V122.21.666.666","article-title":"Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In Myelofibrosis","volume":"122","author":"Bhagwat N","year":"2013","unstructured":"Bhagwat N, Keller MD, Rampal RK, Shank K, de Stanchina E, Rose K, et al. Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In Myelofibrosis. Blood 2013;122:666. https:\/\/doi.org\/10.1182\/BLOOD.V122.21.666.666.","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1182\/BLOOD.V124.21.712.712","article-title":"Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis","volume":"124","author":"Gupta V","year":"2014","unstructured":"Gupta V, Koschmieder S, Harrison CN, Cervantes F, Heidel FH, Drummond M, et al. Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis. Blood 2014;124:712\u2013712. https:\/\/doi.org\/10.1182\/BLOOD.V124.21.712.712.","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/BLOOD.V118.21.424.424","article-title":"Phase 1 Dose-Escalation Study of PF-04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies","volume":"118","author":"Jamieson C","year":"2011","unstructured":"Jamieson C, Cortes JE, Oehler V, Baccarani M, Kantarjian HM, Papayannidis C, et al. Phase 1 Dose-Escalation Study of PF-04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies. Blood 2011;118:424\u2013424. https:\/\/doi.org\/10.1182\/BLOOD.V118.21.424.424.","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.3109\/10428194.2014.984703","article-title":"Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis","volume":"56","author":"Sasaki K","year":"2015","unstructured":"Sasaki K, Gotlib JR, Mesa RA, Newberry KJ, Ravandi F, Cortes JE, et al. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leuk Lymphoma 2015;56:2092\u20137. https:\/\/doi.org\/10.3109\/10428194.2014.984703.","journal-title":"Leuk Lymphoma"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1152\/AJPLUNG.00011.2013","article-title":"Platelet-derived growth factor-A and sonic hedgehog signaling direct lung fibroblast precursors during alveolar septal formation","author":"McGowan SE","year":"2013","unstructured":"McGowan SE, Mccoy DM. Platelet-derived growth factor-A and sonic hedgehog signaling direct lung fibroblast precursors during alveolar septal formation. Am J Physiol Lung Cell Mol Physiol 2013;305. https:\/\/doi.org\/10.1152\/AJPLUNG.00011.2013.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1172\/JCI37189","article-title":"Hedgehog signaling in biliary fibrosis","volume":"118","author":"Greenbaum LE","year":"2008","unstructured":"Greenbaum LE. Hedgehog signaling in biliary fibrosis. J Clin Invest 2008;118:3263\u20135. https:\/\/doi.org\/10.1172\/JCI37189.","journal-title":"J Clin Invest"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1172\/JCI35875","article-title":"Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans","volume":"118","author":"Omenetti A","year":"2008","unstructured":"Omenetti A, Porrello A, Jung Y, Yang L, Popov Y, Choi SS, et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 2008;118:3331\u201342. https:\/\/doi.org\/10.1172\/JCI35875.","journal-title":"J Clin Invest"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1371\/JOURNAL.PONE.0027941","article-title":"Aberrant Hedgehog ligands induce progressive pancreatic fibrosis by paracrine activation of myofibroblasts and ductular cells in transgenic zebrafish","author":"Jung IH","year":"2011","unstructured":"Jung IH, Jung DE, Park YN, Song SY, Park SW. Aberrant Hedgehog ligands induce progressive pancreatic fibrosis by paracrine activation of myofibroblasts and ductular cells in transgenic zebrafish. PLoS One 2011;6. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0027941.","journal-title":"PLoS One"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/J.AJPATH.2011.12.039","article-title":"Hedgehog-Gli pathway activation during kidney fibrosis","volume":"180","author":"Fabian SL","year":"2012","unstructured":"Fabian SL, Penchev RR, St-Jacques B, Rao AN, Sipil P, West KA, et al. Hedgehog-Gli pathway activation during kidney fibrosis. Am J Pathol 2012;180:1441\u201353. https:\/\/doi.org\/10.1016\/J.AJPATH.2011.12.039.","journal-title":"Am J Pathol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1517\/14728222.2014.927443","article-title":"Hedgehog signaling pathway as key player in liver fibrosis: new insights and perspectives","volume":"18","author":"Yang JJ","year":"2014","unstructured":"Yang JJ, Tao H, Li J. Hedgehog signaling pathway as key player in liver fibrosis: new insights and perspectives. Expert Opin Ther Targets 2014;18:1011\u201321. https:\/\/doi.org\/10.1517\/14728222.2014.927443.","journal-title":"Expert Opin Ther Targets"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1371\/JOURNAL.PONE.0023943","article-title":"Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer","author":"Philips GM","year":"2011","unstructured":"Philips GM, Chan IS, Swiderska M, Schroder VT, Guy C, Karaca GF, et al. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLoS One 2011;6. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0023943.","journal-title":"PLoS One"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1021\/MP200115V","article-title":"Cyclopamine attenuates acute warm ischemia reperfusion injury in cholestatic rat liver: Hope for marginal livers","volume":"8","author":"Pratap A","year":"2011","unstructured":"Pratap A, Panakanti R, Yang N, Lakshmi R, Modanlou KA, Eason JD, et al. Cyclopamine attenuates acute warm ischemia reperfusion injury in cholestatic rat liver: Hope for marginal livers. Mol Pharm 2011;8:958. https:\/\/doi.org\/10.1021\/MP200115V.","journal-title":"Mol Pharm"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/ANNRHEUMDIS-2011-200883","article-title":"Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis","volume":"71","author":"Horn A","year":"2012","unstructured":"Horn A, Kireva T, Palumbo-Zerr K, Dees C, Tomcik M, Cordazzo C, et al. Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Ann Rheum Dis 2012;71:785\u20139. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2011-200883.","journal-title":"Ann Rheum Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1165\/RCMB.2013-0154OC","article-title":"Targeting the hedgehog-glioma-associated oncogene homolog pathway inhibits bleomycin-induced lung fibrosis in mice","volume":"51","author":"Moshai EF","year":"2014","unstructured":"Moshai EF, W\u00e9meau-Stervinou L, Cigna N, Brayer S, Somm\u00e9 JM, Crestani B, et al. Targeting the hedgehog-glioma-associated oncogene homolog pathway inhibits bleomycin-induced lung fibrosis in mice. Am J Respir Cell Mol Biol 2014;51:11\u201325. https:\/\/doi.org\/10.1165\/RCMB.2013-0154OC.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1182\/BLOOD-2007-05-091579","article-title":"Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice","volume":"111","author":"Xing S","year":"2008","unstructured":"Xing S, Ho WT, Zhao W, Ma J, Wang S, Xu E, et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008;111:5109\u201317. https:\/\/doi.org\/10.1182\/BLOOD-2007-05-091579.","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718585","article-title":"GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML","author":"Chaudhry P","unstructured":"Chaudhry P, Singh M, Triche TJ, Guzman M, Merchant AA. GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML. Blood 2017;129. https:\/\/doi.org\/10.1182\/blood-2016-05-718585."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1200\/JCO.23.01115","article-title":"Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed\/Refractory Hodgkin Lymphoma","volume":"42","author":"Aoki T","year":"2024","unstructured":"Aoki T, Jiang A, Xu A, Yin Y, Gamboa A, Milne K, et al. Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed\/Refractory Hodgkin Lymphoma. Journal of Clinical Oncology 2024;42:1077\u201387. https:\/\/doi.org\/10.1200\/JCO.23.01115.","journal-title":"Journal of Clinical Oncology"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13045-017-0527-7\/FIGURES\/2","article-title":"Long-Term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and-II pooled analyses","volume":"10","author":"Verstovsek S","year":"2017","unstructured":"Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, et al. Long-Term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and-II pooled analyses. J Hematol Oncol 2017;10:1\u20136. https:\/\/doi.org\/10.1186\/S13045-017-0527-7\/FIGURES\/2.","journal-title":"J Hematol Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1053\/J.SEMINONCOL.2009.02.005","article-title":"Janus kinase mutations","volume":"36","author":"Levine RL","year":"2009","unstructured":"Levine RL. Janus kinase mutations. Semin Oncol 2009;36:S6. https:\/\/doi.org\/10.1053\/J.SEMINONCOL.2009.02.005.","journal-title":"Semin Oncol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/ASHEDUCATION.V2012.1.561.3807838","article-title":"The spectrum of JAK2-positive myeloproliferative neoplasms","volume":"2012","author":"Kiladjian JJ","year":"2012","unstructured":"Kiladjian JJ. The spectrum of JAK2-positive myeloproliferative neoplasms. Hematology 2012;2012:561\u20136. https:\/\/doi.org\/10.1182\/ASHEDUCATION.V2012.1.561.3807838.","journal-title":"Hematology"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.4049\/JIMMUNOL.178.5.2623","article-title":"The JAK-STAT signaling pathway: input and output integration","volume":"178","author":"Murray PJ","year":"2007","unstructured":"Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007;178:2623\u20139. https:\/\/doi.org\/10.4049\/JIMMUNOL.178.5.2623.","journal-title":"J Immunol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/606819","article-title":"Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm","author":"Fleischman AG","unstructured":"Fleischman AG. Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm. Mediators Inflamm 2015;2015. https:\/\/doi.org\/10.1155\/2015\/606819."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/BLOOD-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama A","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109\u201317. https:\/\/doi.org\/10.1182\/BLOOD-2009-04-214957.","journal-title":"Blood"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe M","year":"2015","unstructured":"Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov 2015;5:316\u201331. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0736.","journal-title":"Cancer Discov"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi A","year":"2011","unstructured":"Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356\u201363. https:\/\/doi.org\/10.1200\/JCO.2010.32.9490.","journal-title":"J Clin Oncol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1084\/JEM.20150556","article-title":"Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression","volume":"213","author":"Klein C","year":"2016","unstructured":"Klein C, Zwick A, Kissel S, Forster CU, Pfeifer D, Follo M, et al. Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression. J Exp Med 2016;213:273\u201390. https:\/\/doi.org\/10.1084\/JEM.20150556.","journal-title":"J Exp Med"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1096\/FJ.08-111096","article-title":"Characterization of sonic hedgehog as a novel NF-kappaB target gene that promotes NF-kappaB-mediated apoptosis resistance and tumor growth in vivo","volume":"23","author":"Kasperczyk H","year":"2009","unstructured":"Kasperczyk H, Baumann B, Debatin KM, Fulda S. Characterization of sonic hedgehog as a novel NF-kappaB target gene that promotes NF-kappaB-mediated apoptosis resistance and tumor growth in vivo. FASEB J 2009;23:21\u201333. https:\/\/doi.org\/10.1096\/FJ.08-111096.","journal-title":"FASEB J"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/AJH.24221","article-title":"Myeloproliferative neoplasms: A decade of discoveries and treatment advances","volume":"91","author":"Tefferi A","year":"2016","unstructured":"Tefferi A. Myeloproliferative neoplasms: A decade of discoveries and treatment advances. Am J Hematol 2016;91:50\u20138. https:\/\/doi.org\/10.1002\/AJH.24221.","journal-title":"Am J Hematol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/LEU.2010.269","article-title":"JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations","volume":"25","author":"Pardanani A","year":"2011","unstructured":"Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 2011;25:218\u201325. https:\/\/doi.org\/10.1038\/LEU.2010.269.","journal-title":"Leukemia"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S1286-4579(99)00250-6","article-title":"TGF-\u03b2 and fibrosis","volume":"1","author":"Branton MH","year":"1999","unstructured":"Branton MH, Kopp JB. TGF-\u03b2 and fibrosis. Microbes Infect 1999;1:1349\u201365. https:\/\/doi.org\/10.1016\/S1286-4579(99)00250-6.","journal-title":"Microbes Infect"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/NRNEPH.2016.48","article-title":"TGF-\u03b2: the master regulator of fibrosis","volume":"12","author":"Meng XM","year":"2016","unstructured":"Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-\u03b2: the master regulator of fibrosis. Nat Rev Nephrol 2016;12:325\u201338. https:\/\/doi.org\/10.1038\/NRNEPH.2016.48.","journal-title":"Nat Rev Nephrol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1046\/J.1523-1747.2002.01641.X","article-title":"Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation","volume":"118","author":"Verrecchia F","year":"2002","unstructured":"Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 2002;118:211\u20135. https:\/\/doi.org\/10.1046\/J.1523-1747.2002.01641.X.","journal-title":"J Invest Dermatol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2869","article-title":"Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry","author":"Giesen C","year":"2014","unstructured":"Giesen C, Wang HAO, Schapiro D, Zivanovic N, Jacobs A, Hattendorf B, et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods 2014. https:\/\/doi.org\/10.1038\/nmeth.2869.","journal-title":"Nat Methods"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nmeth.4391","article-title":"histoCAT: analysis of cell phenotypes and interactions in multiplex image cytometry data","volume":"14","author":"Schapiro D","year":"2017","unstructured":"Schapiro D, Jackson HW, Raghuraman S, Fischer JR, Zanotelli VRT, Schulz D, et al. histoCAT: analysis of cell phenotypes and interactions in multiplex image cytometry data. Nat Methods 2017;14:873\u20136. https:\/\/doi.org\/10.1038\/nmeth.4391.","journal-title":"Nat Methods"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/MOH.0B013E3283439964","article-title":"Targeting myeloproliferative neoplasms with JAK inhibitors","volume":"18","author":"Pardanani A","year":"2011","unstructured":"Pardanani A, Tefferi A. Targeting myeloproliferative neoplasms with JAK inhibitors. Curr Opin Hematol 2011;18:105\u201310. https:\/\/doi.org\/10.1097\/MOH.0B013E3283439964.","journal-title":"Curr Opin Hematol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3978\/J.ISSN.2306-9759.2016.02.03","article-title":"Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-\u03b2","volume":"3","author":"Agarwal A","year":"2016","unstructured":"Agarwal A, Morrone K, Bartenstein M, Zhao ZJ, Verma A, Goel S. Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-\u03b2. Stem Cell Investig 2016;3. https:\/\/doi.org\/10.3978\/J.ISSN.2306-9759.2016.02.03.","journal-title":"Stem Cell Investig"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3978\/J.ISSN.2306-9759.2015.01.02","article-title":"Quantitative analyses of myelofibrosis by determining hydroxyproline","author":"Zhao W","year":"2015","unstructured":"Zhao W, Ho W-TT, Zhao ZJ. Quantitative analyses of myelofibrosis by determining hydroxyproline. Stem Cell Investig 2015;2. https:\/\/doi.org\/10.3978\/J.ISSN.2306-9759.2015.01.02.","journal-title":"Stem Cell Investig"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/CNCR.28441","article-title":"A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea","volume":"120","author":"Verstovsek S","year":"2014","unstructured":"Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 2014;120:513\u201320. https:\/\/doi.org\/10.1002\/CNCR.28441.","journal-title":"Cancer"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/leu.2016.377","article-title":"Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia","volume":"31","author":"Fisher DAC","year":"2016","unstructured":"Fisher DAC, Malkova O, Engle EK, Miner CA, Fulbright MC, Behbehani GK, et al. Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia 2017 31:9 2016;31:1962\u201374. https:\/\/doi.org\/10.1038\/leu.2016.377.","journal-title":"Leukemia 2017"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6580439\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6580439\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T15:22:49Z","timestamp":1749482569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6580439\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":64,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-6580439\/v1","relation":{},"subject":[],"published":{"date-parts":[[2025,5,9]]},"subtype":"preprint"}}